

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22862-0003US1	Application No. 10/598,486
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yu et al.		
		Filing Date August 31, 2006	Group Art Unit 1644	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	5,643,786	07/01/1997	Cohen et al.			
	2	5,788,963	08/04/1998	Murphy et al.			
	3	5,849,589	12/14/1998	Tedder et al.			
	4	5,851,756	12/22/1998	Steinman et al.			
	5	5,994,126	11/30/1999	Steinman et al.			
	6	6,037,135	03/14/2000	Kubo et al.			
	7	6,077,519	06/20/2000	Storkus et al.			
	8	6,458,585	10/01/2002	Vachula et al.			
	9	6,479,286	11/12/2002	Nelson et al.			
	10	6,482,405	11/19/2002	Tahara et al.			
	11	6,514,942	02/04/2003	Ioannides et al.			
	12	6,537,560	03/25/2003	Kawakami et al.			
	13	6,566,395	05/20/2003	Moran			
	14	6,632,459	10/14/2003	Graus et al.			
	15	6,649,645	11/18/2003	McKearn et al.			
	16	7,247,480	07/24/2007	Waldmann et al.			
	17	7,338,929	03/04/2008	Debinski et al.			
	18	2001/0043914	11/22/2001	Mathiowitz et al.			
	19	2002/0034819	03/21/2002	Smith et al.			
	20	2002/0119121	08/29/2002	Vitiello et al.			
	21	2003/0095955	05/22/2003	Noessner et al.			
	22	2003/0185823	10/02/2003	Lum et al.			
	23	2003/0190682	10/09/2003	Law et al.			
	24	2003/0202963	10/30/2003	Crystal et al.			
	25	2004/0072246	04/15/2004	Martin et al.			
	26	2004/0197903	10/07/2004	Pestano			
	27	2004/0203143	10/14/2004	Tjoa et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22862-0003US1	Application No. 10/598,486
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yu et al.		
		Filing Date August 31, 2006	Group Art Unit 1644	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	28	2005/0059151	03/17/2005	Bosch			
	29	2006/0204509	09/14/2006	Harty et al.			
	30	2007/0098776	05/03/2007	Fikes et al.			
	31	2008/0107668	05/08/2008	Philip et al.			

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes No
	32	WO 89/06692	07/27/1989	WIPO			
	33	WO 94/26293	11/24/1994	WIPO			
	34	WO 95/21862	08/17/1995	WIPO			
	35	WO 96/18409	06/20/1996	WIPO			
	36	WO 00/24778	05/04/2000	WIPO			
	37	WO 01/08636	02/08/2001	WIPO			
	38	WO 01/41741	06/14/2001	WIPO			
	39	WO 01/58479	08/16/2001	WIPO			
	40	WO 02/068474	09/06/2002	WIPO			
	41	WO 03/010301	02/06/2003	WIPO			
	42	WO 2005/079581	09/01/2005	WIPO			
	43	WO 2008/039874	04/03/2008	WIPO			
	44	WO 2008/039969	04/03/2008	WIPO			
	45	WO 2008/039974	04/03/2008	WIPO			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	46	AKASAKI et al., "Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model," J. Immunother., 24:106-113 (2001)
	47	AKASAKI et al., "Dendritic cell-based immunotherapy for malignant gliomas," Expert Rev. Neurother., 5:497-508 (2005)
	48	AKASAKI et al., "Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma," J. Immunol., 173:4352-59 (2004)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22862-0003US1	Application No. 10/598,486
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yu et al.	
		Filing Date August 31, 2006	Group Art Unit 1644

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	49	AKASAKI et al., "T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches," <i>Front. Biosci.</i> , 10:2908-21 (2005)
	50	AKBARI et al., "Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen," <i>Nat. Immunol.</i> , 2:725-731 (2001)
	51	BASU et al., "Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO," <i>J. Immunol.</i> , 17:2391-2402 (2006)
	52	BOWLES, JR. et al., "Long-term remission of malignant brain tumors after intracranial infection: a report of four cases," <i>Neurosurgery</i> , 44:636-642 (1999)
	53	CANDIDO et al., "Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents," <i>Cancer Res.</i> , 61:228-236 (2001)
	54	CASTRO et al., "Current and future strategies for the treatment of malignant brain tumors," <i>Pharmacol. Ther.</i> , 98:71-108 (2003)
	55	CHANDLER et al., "Long-term survival in patients with glioblastoma multiforme," <i>Neurosurgery</i> , 32:716-720 (1993)
	56	CHUI et al., "Dendritic cell vaccination following high dose chemotherapy with autologous stem cell support for breast cancer: long-term follow-up," <i>Proc. Am. Soc. Clin. Oncol.</i> , 22, abstract (2003)
	57	CURRAN et al., "Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials," <i>J. Natl. Cancer Inst.</i> , 85:704-710 (1993)
	58	DIETZ, "Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia," <i>Croatian Med. J.</i> , 42:428-435 (2001)
	59	EHTESHAM et al., "Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials," <i>Cancer Control</i> , 11:192-207 (2004)
	60	GILBOA et al., "Immunotherapy of cancer with dendritic-cell-based vaccines," <i>Cancer Immunol. Immunother.</i> , 46:82-87 (1998)
	61	GROUX et al., "Intelreukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells," <i>J. Exp. Med.</i> , 184:19-29 (1996)
	62	HARIZI et al., "Cyclooxygenase-2-issued prostaglandin E2 enhances the production of endogenous IL-10, which down-regulates dendritic cell functions," <i>J. Immunol.</i> , 168:2255-63 (2002)
	63	HEIMBERGER et al., "Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma," <i>J. Neuroimmunol.</i> , 103:16-24 (2000)
	64	INOUE et al., "Dendritic cells coinjected with tumor cells treated with an anticancer drug to induce tumor rejection," <i>Surg. Today</i> , 33:269-276 (2003)
	65	KABASHIMA et al., "Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells," <i>Nat. Med.</i> , 9:744-749 (2003)
	66	KIKUCHI et al., "Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model," <i>Cancer Immunol. Immunother.</i> , 51:424-430 (2002)
	67	KIKUCHI et al., "Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells," <i>Cancer Immunol. Immunother.</i> , 50:337-344 (2002)
	68	KNUTSON et al., "Technology evaluation: DCVax, Northwest Biotherapeutics," <i>Curr. Opin. Mol. Ther.</i> , 4:403-407 (2002)
	69	LEE et al., "The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells," <i>J. Immunother.</i> , 32:22-28 (2009)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22862-0003US1	Application No. 10/598,486
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yu et al.	
		Filing Date August 31, 2006	Group Art Unit 1644

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	70	LEGLER et al., "Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors," <i>J. Immunol.</i> , 176:966-973 (2006)
	71	LESLIE, "Properties and regulation of cytosolic phospholipase A2," <i>J. Biol. Chem.</i> , 272:16709-12 (1997)
	72	LEVINGS et al., "Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+ CD4+ Tr cells," <i>Blood</i> , 105:1162-69 (2005)
	73	LIAU et al., "Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens," <i>J. Neurosurg.</i> , 90:1115-24 (1999)
	74	LIU and YU, "Cancer vaccines: a novel strategy to sensitize malignant glioma to chemotherapy," <i>Expert Rev. Neurother.</i> , 7:1235-37 (2007)
	75	LIU et al., "Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response," <i>Eur. J. Immunol.</i> , 34:1680-87 (2004)
	76	LIU et al., "Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma," <i>J. Immunother.</i> , 26:301-312 (2003)
	77	LUFT et al., "Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets," <i>Blood</i> , 100:1362-72 (2002)
	78	LUPTRAWAN et al., "Dendritic cell immunotherapy for malignant gliomas," <i>Rev. Recent Clin. Trials</i> , 3:10-21 (2008)
	79	MAHIC et al., "FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism," <i>J. Immunol.</i> , 177:246-254 (2006)
	80	MEHTA-DAMANI et al., "Generation of antigen-specific CD4+ T cell lines from naïve precursors," <i>Eur. J. Immunol.</i> , 5:1206-11 (1995)
	81	MEHTA-DAMANI et al., "Generation of antigen-specific CD8+ CTLs from naive precursors," <i>J. Immunol.</i> , 153:996-1003 (1994)
	82	MERRICK et al., "Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy," <i>Cancer Immunol. Immunother.</i> , 57:897-906 (2008)
	83	NOWAK et al., "Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors," <i>Cancer Res.</i> , 63:4490-96 (2003)
	84	OKADA et al., "Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms," <i>Int. J. Cancer</i> , 78:196-201 (1998)
	85	OKADA et al., "Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy," <i>J. Neurooncol.</i> , 64:13-20 (2003)
	86	OSADA et al., "Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report," <i>Jpn. J. Clin. Oncol.</i> , 31:403-406 (2001)
	87	POCKAJ et al., "Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer," <i>Ann. Surg. Oncol.</i> , 11:328-339 (2004)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22862-0003US1	Application No. 10/598,486
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yu et al.		
		Filing Date August 31, 2006	Group Art Unit 1644	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	88	POLLACK et al., "Exploitation of immune mechanisms in the treatment of central nervous system cancer," <i>Semin. Pediatr. Neurol.</i> , 7:131-143 (2000)
	89	REICHARDT et al., "Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells," <i>Haematologica</i> , 88:1139-49 (2003)
	90	SCANDELLA et al., "CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2," <i>Blood</i> , 103:1595-1601 (2004)
	91	SHIN et al., "Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model," <i>Histol. Histopathol.</i> , 18:435-447 (2003)
	92	STEINBRINK et al., "CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity," <i>Blood</i> , 99:2468-76 (2002)
	93	STEINMAN et al., "The induction of tolerance by dendritic cells that have captured apoptotic cells," <i>J. Exp. Med.</i> , 191:411-416 (2000)
	94	STEINMAN et al., "Tolerogenic dendritic cells," <i>Annu. Rev. Immunol.</i> , 21:685-711 (2003)
	95	STEINMAN, "Some interfaces of dendritic cell biology," <i>APMIS</i> , 111:675-697 (2003)
	96	STUPP et al., "Recent Developments in the Management of Malignant Glioma," <i>American Society of Clinical Oncology Educational Book</i> , 779-788 (2003)
	97	TANAKA et al., "Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo," <i>Int. J. Cancer</i> , 101:265-269 (2002)
	98	TONG et al., "Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors," <i>Cancer Res.</i> , 61:7530-35 (2001)
	99	WHEELER et al., "Cellular immunity in the treatment of brain tumors," <i>Clin. Neurosurg.</i> , 51:132-139 (2004)
	100	WHEELER et al., "Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination," <i>Clin. Cancer Res.</i> , 10:5316-26 (2004)
	101	WHEELER et al., "Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality," <i>J. Immunol.</i> , 171:4927-33 (2003)
	102	WHEELER et al., "Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients," <i>Cancer Res.</i> , 68:5955-64 (2008)
	103	YAMAZAKI et al., "Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells," <i>J. Exp. Med.</i> , 198:235-247 (2003)
	104	YOUNG et al., "Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells," <i>J. Exp. Med.</i> , 171:1315-32 (1990)
	105	YU et al., "Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer," <i>Clin. Cancer Res.</i> , 9:285-294 (2003)
	106	YU et al., "Mahaley Clinical Research Award: chemosensitization of glioma through dendritic cell vaccination," <i>Clin. Neurosurg.</i> , 53:345-351 (2006)
	107	YU et al., "Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma," <i>Cancer Res.</i> , 64:4973-79 (2004)
	108	ZHANG et al., "Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics," <i>Clin. Cancer Res.</i> , 13:566-575 (2007)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	